Quick Answer
Lantern Pharma Inc. reported Operating Income Loss of -$17.98 million for the year ending 2025.
- Lantern Pharma Inc. showed an increase of +19.1% in Operating Income Loss from 2024 to 2025.
- This data is from Lantern Pharma Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$833.4 thousand | Q3 2020: -$1.70 million | Q2 2021: -$2.48 million | Q3 2021: -$4.15 million | Q1 2022: -$4.07 million | Q2 2022: -$4.39 million | Q3 2022: -$2.15 million | Q1 2023: -$4.29 million | Q2 2023: -$5.19 million | Q3 2023: -$3.52 million | Q1 2024: -$5.73 million | Q2 2024: -$5.41 million | Q3 2024: -$5.18 million | Q1 2025: -$4.77 million | Q2 2025: -$4.65 million | Q3 2025: -$4.35 million.
- Over the full 5 years of available data (2021 to 2025), Lantern Pharma Inc.'s Operating Income Loss has declined by 42.8%.
- Historical annual values: Fiscal year 2025: -$17.98 million | Fiscal year 2024: -$22.22 million | Fiscal year 2023: -$17.88 million | Fiscal year 2022: -$14.43 million | Fiscal year 2021: -$12.59 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: